Lupin announced that it has received approval for its Atovaquone Oral Suspension USP, 750 mg/5 mL from the United States Food and Drug Administration (FDA) to market a generic version of GlaxoSmithKline LLC's Mepron Oral Suspension, 750 mg/5 mL.
Lupin's Atovaquone Oral Suspension USP, 750 mg/5 mL is the generic version of GlaxoSmithKline LLC's Mepron Oral Suspension, 750 mg/5 mL. It is indicated for prevention and acute oral treatment of mild-tomoderate Pneumocystis carinii pneumonia (PCP) in patients intolerant to trimethoprim-sulfamethoxazole (TMP-SMX).
Atovaquone Oral Suspension, 750 mg/5 mL had annual sales of approximately USD 117.4 million in the US (IQVIA MAT June 2018).
Shares of LUPIN LTD. was last trading in BSE at Rs.956.35 as compared to the previous close of Rs. 939.6. The total number of shares traded during the day was 202127 in over 4876 trades.
The stock hit an intraday high of Rs. 960 and intraday low of 922. The net turnover during the day was Rs. 190861123.